Keywords: UK, NICE, SMC, Novartis, Afinitor, Tasigna, Bristol-Meyes Squibb, Sprycel, EliLilly, Alimta, Janssen Cilag, Stelara

UK’s NICE says “no” to Novartis’ Afinitor for advanced RCC and delays Sprycel and Tasigna; Scotland backs Alimta and Stelara

Article | 09 February 2010

Print This

In draft guidance, published today, the UK’s National Institute for Health and Clinical Excellence (NICE) says it has been ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in